0000950170-24-027442.txt : 20240306
0000950170-24-027442.hdr.sgml : 20240306
20240306184539
ACCESSION NUMBER: 0000950170-24-027442
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240305
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoey Timothy
CENTRAL INDEX KEY: 0001553333
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40656
FILM NUMBER: 24727593
MAIL ADDRESS:
STREET 1: C/O TENAYA THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BOULEVARD, 5TH FLR.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tenaya Therapeutics, Inc.
CENTRAL INDEX KEY: 0001858848
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813789973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD., SUITE 500
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-865-2066
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD., SUITE 500
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-03-05
0001858848
Tenaya Therapeutics, Inc.
TNYA
0001553333
Hoey Timothy
C/O TENAYA THERAPEUTICS, INC.
171 OYSTER POINT BLVD., 5TH FLOOR
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Scientific Officer
true
Common Stock
2024-03-05
4
S
false
3300
7.0003
D
245346
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.01. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Includes 50,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2024-03-06